Oncolytics Biotech announces its financial results and operational highlights for the second quarter 2014

Oncolytics Biotech announces its financial results and operational highlights for the second quarter 2014 -

Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ( "Oncolytics" or the "Company") today announced its financial results and operational highlights for the second quarter ended June 30, 2014.

"Our randomized clinical program continued to rise during the quarter, have recently reported the completion of enrollment in a Phase II trial using REOLYSIN ^® in combination with carboplatin and paclitaxel in patients with pancreatic cancer, "said Dr. Brad Thompson, President and CEO of Oncolytics. "We also strengthened our Board, adding two directors with significant experience in financial and public society."

selected Highlights

Since 1 April 2014, highlights announced by the Company include:

the clinical and preclinical data

• completion patient enrollment in a study two arm randomized phase II of carboplatin, paclitaxel plus REOLYSIN ^® against carboplatin and paclitaxel alone in the first-line treatment of patients with recurrent or metastatic pancreatic cancer (OSU-10045);
• the first results of a study looking translational intravenous administration of REOLYSIN ^® for patients with primary or metastatic brain tumors was presented at the annual ASCO meeting Chicago, IL;
• final data from randomized clinical double-blind study of examining Company REOLYSIN ^® in combination with carboplatin and paclitaxel in patients with second-line of the head and neck cancers naive taxane refractory plate;
• A series of presentations by research collaborators in 8 ^e Annual International Confe ^r ence on Therapeutics oncolytic viruses held in Oxford, United Kingdom covering
  • early clinical research showing that intravenous REOLYSIN delivered ^® can cross the blood-brain barrier to reach the tumor in the human brain;
  • preclinical research examining the synergies associated with the treatment in animal models with GM-CSF prior to administration of REOLYSIN ^®
  • preclinical research focusing on the identification of biomarkers predictive of sensitivity / resistance to reovirus in cell lines of head and neck cancer; and
  • preclinical research in hepatocellular carcinoma treatment associated with infection with hepatitis B and hepatitis C.

governance

• the nomination and election of Linda Hohol and Angela Holtham to the Board of the administration Corporation; and

financial

• On June 30, 2014, the company reported $ 18.9 million in cash, cash equivalents and investments short term.